News BioSenic SA

Equities

BIOS

BE0974280126

Market Closed - Euronext Bruxelles Other stock markets 11:26:32 2024-04-23 am EDT			5-day change	1st Jan Change
0.0196 ^EUR	-4.85%		-11.71%	-67.97%

Apr. 11	Biosenic: launch of a debt restructuring plan	CF
Mar. 12	Biosenic S.A. Releases Details of Optimized Administration Approach Ahead of Planned Phase 3 Trial of OATO for Chronic Graft-Versus-Host Disease	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioSenic S.A. : Transparency notifications received from François Rieger	Apr. 18	GL
BioSenic provides further information on its restructuring plan	Apr. 12	GL
BioSenic : summary bonds refinancing_20240411	Apr. 12	PU
Biosenic: launch of a debt restructuring plan	Apr. 11	CF
BioSenic and its restructuring practitioner (Me Yves Brulard) submit a global restructuring plan covering the years 2024-2030 to the Enterprise Court of Nivelles	Apr. 11	GL
BioSenic and its restructuring practitioner (Me Yves Brulard) submit a global restructuring plan covering the years 2024-2030 to the Enterprise Court of Nivelles	Apr. 11	AQ
BioSenic presents successful preclinical data on its ATO medication for controlling key symptoms at the 2024 Systemic Sclerosis World Congress	Mar. 20	GL
BioSenic releases details of optimized administration approach ahead of planned Phase 3 trial of OATO for chronic graft-versus-host disease	Mar. 12	GL
Biosenic S.A. Releases Details of Optimized Administration Approach Ahead of Planned Phase 3 Trial of OATO for Chronic Graft-Versus-Host Disease	Mar. 12	CI
BioSenic Raises Capital to Fund US FDA Application for Oral Arsenic Trioxide	Feb. 05	MT
BioSenic raises €500,000 in private placement of new shares with established new investors	Feb. 02	GL
BioSenic S.A. announced that it has received ?0.5 million in funding from Société Boursier.com SA, Gestys Sprl, Friedland Gestion	Feb. 01	CI
BioSenic provides support to forthcoming European conference on graft-versus-host disease	Jan. 31	GL
BioSenic Unit Wins Canadian Patent for Therapeutic Platform	Jan. 30	MT
BioSenic patent granted in Canada for broader protection of ATO therapeutic platform	Jan. 30	GL
BioSenic S.A. Patent Granted in Canada for Broader Protection of ATO Therapeutic Platform	Jan. 30	CI
BioSenic presents new Phase 3 data on JTA-004 to treat severe osteoarthritis pain at the 2024 OARSI World Congress	Jan. 25	GL
BioSenic presents new Phase 3 data on JTA-004 to treat severe osteoarthritis pain at the 2024 OARSI World Congress	Jan. 25	AQ
BioSenic Presents New Phase 3 Data on JTA-004 to Treat Severe Osteoarthritis Pain at the 2024 OARSI World Congress	Jan. 25	CI
BioSenic Files US Patent for Osteoarthritis Therapy	Jan. 23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News BioSenic SA

Equities

BIOS

BE0974280126

Summary

Filters